These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8748619)

  • 1. Pharmacokinetics of apomorphine in Parkinson's disease.
    Gancher S
    J Neural Transm Suppl; 1995; 45():137-41. PubMed ID: 8748619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
    van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
    Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral pharmacokinetics of apomorphine in humans.
    Gancher ST; Woodward WR; Boucher B; Nutt JG
    Ann Neurol; 1989 Aug; 26(2):232-8. PubMed ID: 2774511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
    van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
    Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
    Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
    LeWitt PA
    Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
    Neef C; van Laar T
    Clin Pharmacokinet; 1999 Sep; 37(3):257-71. PubMed ID: 10511920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia.
    Harder S; Baas H; Demisch L; Simon E
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):355-62. PubMed ID: 9707348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
    Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
    Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of dopamine agonists in Parkinson's disease: an update.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 20. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.